88
New Monoclonal Antibody for RSV Prevention Arrives in the Marche Region
The Marche region in France has announced the arrival of a new monoclonal antibody to prevent serious respiratory infections caused by the respiratory syncytial virus (RSV). This preventative measure is aimed at newborns and young children during their first RSV season.
How it works:
- Nirsevimab, the monoclonal antibody, offers immediate protection against RSV infections.
- A single administration is sufficient for the entire autumn/winter risk season.
- The antibody has been shown to be safe and effective in reducing the need for medical intervention for RSV-related respiratory infections.
Benefits:
- Reduces RSV respiratory infections requiring medical assistance by 80%.
- Reduces RSV respiratory infections requiring hospitalization by 77%.
Target audience:
- Newborns born between October 2024 and March 2025 can receive the antibody directly in the hospital before discharge.
- Children born between April and September 2024 can be vaccinated by pediatricians or vaccination services.
Motivation:
- RSV is a dangerous virus that can cause severe infections, particularly among young children.
- The lack of specific treatments for serious RSV infections highlights the need for preventative measures.
Call to action:
The antibody is available through voluntary adherence in the Marche region. Consult with your pediatrician or healthcare provider for more information and eligibility.